www.stockwire.com is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Activity on the NYSE market has brought this company to the attention of our research team. CVS/pharmacy (NYSE:CVS)
CVS Caremark Corporation (NYSE: CVS) announced that same store sales (sales from retail pharmacy stores open more than one year) in its CVS/pharmacy division for the four weeks ended May 26, 2007 increased 6.2% over the prior year period. Pharmacy same store sales increased 6.0%, and were negatively impacted by approximately 590 basis points due to recent generic introductions. Front-end same store sales increased 6.6%. Same store sales do not include the drugstores acquired on June 2, 2006, which will be included in same store sales following the one-year anniversary of the acquisition, beginning in fiscal July 2007.
Same store sales at CVS/pharmacy for the twenty one week period increased 6.8% over the prior year period. Pharmacy same store sales increased 7.1%, while front-end same store sales increased 6.1%.
During the four week period ended May 26, 2007, the Company opened 15 new stores, closed 5 stores and relocated 5 others. As of May 26, 2007, the Company operated 6,168 CVS/pharmacy stores in 40 states and the District of Columbia.
About CVS Caremark
CVS Caremark is the #1 provider of prescriptions and related healthcare services in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of healthcare services in the U.S. The Company is uniquely positioned to effectively manage costs and improve healthcare outcomes through its approximately 6,200 CVS/pharmacy stores; its pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations portion of the Company's website, at http://investor.cvs.com, as well as through the pressroom portion of the Company's website, at www.cvs.com/pressroom.
During morning trading shares are up .5% to $38.74 with over 2 million in volume. The STOCKWIRE Research Team will continue to gauge the short and long term affects that this announcement will have on the company
For a complimentary subscription to the newest and most exciting online financial newsletter on the market, visit www.stockwire.com.
The Financial Information and Financial Content provided by Stockwire.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Stockwire.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Stockwire.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Stockwire.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.
All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Stockwire to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stockwireis not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
